Treatment Information

Back

Melanoma treatment details. Chemotherapy, Biologic therapy.

Churchill Hospital, Oxford, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Oxford
Treatments:Chemotherapy, Biologic therapyHospital:Churchill Hospital
Drugs:Journal:Link
Date:Feb 2014

Description:

Patients:
This phase 2 study involved advanced melanoma patients with the wild-type BRAF gene who were divided into two different treatment groups. Group A consisted of 41 patients with a median age of 62 years, 76% of whom were male. Group B had 42 patients with a median age of 63 years, 64% of whom were male.

Treatment:
Patients in group A received chemotherapy with docetaxel and biologic therapy with selumetinib (a kinase inhibitor that interferes with cancer cell growth).

Patients in group B received chemotherapy with docetaxel and a placebo.

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 fatigue, febrile neutropenia, and rash.

The most severe toxicities in group B were of grade 4 and included grade 3-4 pain, nerve toxicity, and fatigue.

Results:
The median overall survival rates for groups A and B were 9.5 and 11.37 months, respectively.

Support:
This study was partially supported by AstraZeneca.

Correspondence: Dr. M. R. Middleton; email: [email protected]



Back